InvestorsHub Logo
Followers 50
Posts 9243
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Friday, 09/20/2024 5:20:08 AM

Friday, September 20, 2024 5:20:08 AM

Post# of 13634
With Pfizer hitting a stumbling block, Moderna’s COVID-19/influenza vaccine, mRNA-1083, could be the first such combination vaccine to reach the market. In June, the company posted results from a Phase III trial that showed mRNA-1083 produced a strong immune response against both COVID-19 and influenza. In releasing the results, Moderna also became the first and, due to Pfizer/BioNTech’s struggles, only company to date to post positive Phase III results for a combination COVID-19/influenza vaccine.

https://www.biospace.com/drug-development/5-late-stage-mrna-vaccines-to-watch
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News